THE US ONCOLOGY NETWORK selected Myriad Genetics as its preferred provider laboratory for hereditary cancer testing. As part of the collaboration, Myriad and The US Oncology Network will work together to perform hereditary cancer research through the Genetic Risk Evaluation and Testing program within The Network affiliated practices. Under this program, the two organizations will...
More than a year after a catastrophic shortage of platinum-based chemotherapy drugs swept through the U.S., FDA on June 28 officially removed carboplatin and cisplatin from the drug shortage list.
